Early antigen test marks imperfect step toward mass screening
The FDA announced a Quidel antigen test that can quickly detect some active COVID-19 cases but is less accurate than genetic tests and requires specialized equipment. Experts say it could expand screening and speed results, yet misses some infections and needs confirmatory testing.
MENTIONED IN THIS ARTICLE
Washington
U.S
Food and Drug Administration
Patricia Simner
Johns Hopkins University
Scott Gottlieb
FDA
CBS
Abbott Laboratories
Harvard
White House
Deborah Birx
National Institutes of Health
Simner
Johns Hopkins
OraSure Technologies
OraSure
Stephen Tang
Also Mentioned on This Page
Quidel Corp
Robin Patel
The
Mayo Clinic
Armstrongonewire.com
Armstrong
ClevelandClinic.org
Cleveland Clinic
DOC
Comstock
Sewing & Vacuum Center
Doc’s
Medina
Jim Watson
North Court St